1. Inicio
  2. Publicaciones
  3. Targeted Delivery of The Pan-Inflammasome Inhibitor MM01 as An Alternative Approach to Acute Lung Injury Therapy.

Targeted Delivery of The Pan-Inflammasome Inhibitor MM01 as An Alternative Approach to Acute Lung Injury Therapy.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Garcia-Fernandez, Alba
  • Sancho, Monica
  • Orzaez, Mar

Grupos

Abstract

Acute lung injury (ALI) is a severe pulmonary disorder responsible for high percentage of mortality and morbidity in intensive care unit patients. Current treatments are ineffective, so the development of efficient and specific therapies is an unmet medical need. The activation of NLRP3 inflammasome during ALI produces the release of proinflammatory factors and pyroptosis, a pro-inflammatory form of cell death that contributes to lung damage spreading. Here, we demonstrate that modulating inflammasome activation through inhibition of ASC oligomerization by the recently described MM01 compound could be an alternative pharmacotherapy against ALI. Besides, we determine the added efficacy of using a drug delivery nanosystem designed to target the inflamed lungs. The MM01 drug is incorporated into mesoporous silica nanoparticles capped with a peptide (TNFR-MM01-MSNs) to target TNFR-1 receptor to pro-inflammatory macrophages. The prepared nanoparticles can deliver the cargo in a controlled manner after the preferential uptake by pro-inflammatory macrophages and exhibit anti-inflammatory activity. Finally, the therapeutic effect of MM01 free or nanoparticulated to inhibit inflammatory response and lung injury is successfully demonstrated in LPS-mouse model of ALI. The results suggest the potential of pan-inflammasome inhibitors as candidates for ALI therapy and the use of nanoparticles for targeted lung delivery. This article is protected by copyright. All rights reserved.

This article is protected by copyright. All rights reserved.

Datos de la publicación

ISSN/ISSNe:
2192-2640, 2192-2659

Advanced Healthcare Materials  John Wiley and Sons Ltd

Tipo:
Article
Páginas:
2301577-2301577
PubMed:
37515468
Factor de Impacto:
2,015 SCImago ℠
Cuartil:
Q1 SCImago ℠

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Acute lung injury; MM01; Mesoporous silica nanoparticles; Targeted-lung delivery

Proyectos y Estudios Clínicos

NANOMATERIALES INTELIGENTES, SONDAS Y DISPOSITIVOS PARA EL DESARROLLO INTEGRADO DE NUEVAS HERRAMIENTAS APLICADAS AL CAMPO BIOMÉDICO

Investigador Principal: JUAN BAUTISTA SALOM SANVALERO

MAT2015-64139-C4-1-R . MINISTERIO DE ECONOMIA Y COMPETITIVIDAD . 2016

PROGRAMA TÉCNICO DE APOYO. MODALIDAD INFRAESTRUCTURA.

Investigador Principal: RAMÓN MARTÍNEZ MÁÑEZ

PTA2016-12603-1 . MINISTERIO DE ECONOMIA Y COMPETITIVIDAD . 2018

PLATAFORMA PARA LA DETECCIÓN DE PATÓGENOS BASADA EN MATERIALES CON PUERTAS MOLECULARES (PATH-GATE).

Investigador Principal: RAMÓN MARTÍNEZ MÁÑEZ

DTS18/00090 . INSTITUTO DE SALUD CARLOS III . 2019

Contrato i-PFIS Doctorados IIS - empresa en Ciencias y Tecnologías de la Salud.

Investigador Principal: FÉLIX SANCENÓN GALARZA

IFI19/00026 . INSTITUTO DE SALUD CARLOS III . 2020

ESTUDIO FASE II CON ALEATORIZACIÓN 2:1 PARA COMPARAR LA EFICACIA Y SEGURIDAD DEL TRATAMIENTO CON QUIMIOTERAPIA ESTÁNDAR MÁS QUIZARTINIB FRENTE A QUIMIOTERAPIA ESTÁNDAR MÁS PLACEBO EN PACIENTES ADULTOS CON LMA DE NUEVO DIAGNÓSTICO CON EL GEN FLT3 NO MUTADO.

Investigador Principal: REBECA RODRÍGUEZ VEIGA

QUIWI . 2019

Contratos Sara Borrell 2020. DIEZ SÁNCHEZ, PAULA

Investigador Principal: FÉLIX SANCENÓN GALARZA

CD20/00120 . INSTITUTO DE SALUD CARLOS III . 2021

Plataforma ISCIII de Biobancos y Biomodelos

Investigador Principal: JOSÉ VICENTE CERVERA ZAMORA

PT20/00179 . INSTITUTO DE SALUD CARLOS III . 2021

SIPRALDPE - UCIE 22-24

Investigador Principal: MANUEL MIRALLES HERNÁNDEZ

INNVA2/2022/1_SPIRALDPE . FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2022

Cita

Compartir